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Abstract
Overexpression of the GRP78 receptor on cell surfaces has been linked with tumor growth, 
metastasis, and resistance to therapy. We developed a 64Cu-labeled probe for PET imaging of 
tumor GRP78 expression based on a novel anti-GRP78 monoclonal antibody, MAb159.
Methods—MAb159 was conjugated with the 64Cu-chelator DOTA through lysines on the 
antibody. DOTA–human IgG was also prepared as a control that did not bind to GRP78. The 
resulting PET probes were evaluated in BXPC3 pancreatic cancer xenografts in athymic nude 
mice.
Results—The radiotracer was synthesized with a specific activity of 0.8 MBq/μg of antibody. In 
BXPC3 xenografts, 64Cu-DOTA-MAb159 demonstrated prominent tumor accumulation (4.3 
± 1.2, 15.4 ± 2.6, and 18.3 ± 1.0 percentage injected dose per gram at 1, 17, and 48 after injection, 
respectively). In contrast, 64Cu-DOTA–human IgG had low BXPC3 tumor accumulation (4.8 
± 0.5, 7.5 ± 0.7, and 4.6 ± 0.8 percentage injected dose per gram at 1, 17, and 48 h after injection, 
respectively).
Conclusion—We demonstrated that GRP78 can serve as a valid target for pancreatic cancer 
imaging. The success of this approach will be valuable for evaluating disease course and 
therapeutic efficacy at the earliest stages of anti-GRP78 treatment. Moreover, these newly 
For correspondence or reprints contact either of the following: Zibo Li, Department of Radiology and Biomedical Research Imaging 
Center, University of North Carolina-Chapel Hill, 125 Mason Farm Rd., Marsico Hall, Ste. 1200, Chapel Hill, NC 27599. 
ziboli@med.unc.edu; Hong Shan, Department of Radiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, 
China. shanhong@mail.sysu.edu.cn.
*Contributed equally to this work.
Disclosure: No other potential conflict of interest relevant to this article was reported.
HHS Public Access
Author manuscript
J Nucl Med. Author manuscript; available in PMC 2017 May 30.
Published in final edited form as:













developed probes may have important applications in other types of cancer overex-pressing 
GRP78.
Keywords
GRP78; PET; 64Cu; pancreatic cancer
Pancreatic cancer is the fifth leading cause of cancer-related death, because it is resistant to 
chemotherapy and often is not detected until a late stage, when metastases are present (1,2). 
Surgical treatment provides the best prognosis for patients who have early-stage disease. 
Thus, new imaging methods for early detection of pancreatic cancer, and clinically effective 
methods of monitoring response to therapy, are critical to increasing survival in pancreatic 
cancer patients.
The glucose-regulated protein GRP78, also known as immuno-globulin heavy-chain binding 
protein, was discovered in the late 1970s as a cellular protein induced by glucose starvation. 
In human cancers, an elevated GRP78 level generally correlates with higher pathologic 
grade, recurrence, and poor survival in patients with breast, liver, prostate, colon, or gastric 
cancers (3). Although GRP78 expression is maintained at a low basal level in major adult 
organs such as the brain, lung, and heart, it is strongly induced in tumors (4,5). In addition, 
glucose starvation resulting from poor perfusion within tumors could induce surface 
relocalization of GRP78 (3,6,7).
Recently, a monoclonal antibody, MAb159, against GRP78 was developed to target surface 
GRP78 and block its oncogenic functions (8). MAb159 has been found to suppress 
phosphatidylinositol-3′-kinase/protein kinase B (Akt) signaling, induce apoptosis, and 
induce tumor regression in xenografts and spontaneous tumor models. The humanized 
MAb159 retains its GRP78-binding affinity and efficacy and is nontoxic to normal organs. 
MAb159 will soon be tested on humans.
A noninvasive PET imaging probe that can visualize and quantify GRP78 expression in vivo 
is needed to meet the future demand for anti-GRP78 cancer therapy. Herein, we report a 
novel MAb159-based PET probe and its small-animal imaging results.
Materials and Methods
Unless noted otherwise, all chemicals were of analytic grade and purchased from Sigma-
Aldrich. DOTA analogs were purchased from Macrocyclics, Inc. Size-exclusion PD-10 
columns were purchased from GE Healthcare. The monoclonal antibody, MAb159, was 
kindly provided by Vasgene Therapeutics, Inc. Human IgG (hIgG) was purchased from 
Rockland Immunochemicals Inc. CD31 antibody was from BD Pharmingen. The secondary 
antibodies goat anti-human Alexa Fluor 568 and goat anti-rat Alexa Fluor 488 were 
purchased from Invitrogen. Cy5.5 N-hydroxysuccinimide (Cy5.5-NHS) ester was purchased 
from Lumiprobe Corp. 64Cu was obtained from Washington University and the University of 
Wisconsin. 64Cu was produced using the 64Ni (p,n) 64Cu nuclear reaction and supplied in 
high specific activity as 64CuCl2 in 0.1N HCl.
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MAb159 and hIgG were conjugated with DOTA using a method published previously (9). 
DOTA was first activated to DOTA-N-hydroxysulfosuccinimidyl (DOTA-NHS) as 
previously reported (10). Without purification, DOTA-NHS was cooled to 4°C and added to 
the MAb159 or hIgG in 0.1 M borate buffer (pH 8.5). The reaction mixture was incubated at 
4°C for 10 h. DOTA-MAb159 or DOTA-hIgG conjugates were purified using a PD-10 
column and concentrated by a Centricon filter (Millipore). The final concentration was 
calculated on the basis of ultraviolet absorbance at 280 nm using unconjugated antibody of 
known concentrations as a standard. Both DOTA-MAb159 and DOTA-hIgG were labeled 
with 64Cu using the same method. The DOTA-MAb159 or DOTA-hIgG (25–50 μg) was 
added to 64CuCl2 (37–74 MBq of 64Cu). The reaction mixture was adjusted to pH 5.5 with 
0.1N sodium acetate and incubated for 1 h at 40°C with constant shaking. The 64Cu-labeled 
antibody conjugates were then purified by a PD-10 column using 1× phosphate-buffered 
saline as the eluent. The radioactive fraction containing 64Cu-DOTA-MAb159 or 64Cu-
DOTA-hIgG was collected for further in vitro and in vivo experiments. 5(6)-
carboxyfluorescein (FAM)-MAb159 was synthesized as reported previously (11,12). FAM 
succinimidyl ester (FAM-NHS) and MAb159 were mixed at a ratio of 1:1 at pH 8.5. FAM-
MAb159 was obtained after incubation at room temperature for 1.5 h and purification with a 
PD-10 column. Synthesis of Cy5.5-MAb159 and Cy5.5-hIgG is described in supplemental 
materials (available at http://jnm.snmjournals.org).
Cell Lines and Animal Model
A human pancreatic cancer cell line (BXPC3) and human lung cancer cell line (NCI-H249) 
were obtained from American Type Culture Collection and cultured under the recommended 
conditions. Tumor models were established in 4- to 6-wk-old female athymic nude mice 
obtained from Harlan. Cells were used for in vitro and in vivo experiments when they 
reached 80%–90% confluence. The GRP78 expression levels on cell lines under high- or 
low-glucose conditions were evaluated using Western blotting. In brief, approximately 20 μg 
of whole-cell lysates were run on 4%–20% tris-glycine gradient gel (Bio-Rad) and 
transferred onto nitrocellulose membrane (Bio-Rad). The membrane was blocked with 5% 
nonfat dry milk in Tris-buffered saline and 0.05% polysorbate-20 for 40 min and then 
incubated overnight with a 1 μg/mL concentration of primary antibody at 4°C. The 
membrane was washed 3 times for 10 min each and incubated with secondary horseradish 
peroxidase–labeled or IRDye-labeled antibody for 40 min. After 3 washings with Tris-
buffered saline and 0.05% polysorbate-20, horseradish peroxidase signal was detected using 
Femto maximum-sensitivity chemiluminescent sub-strate (Thermo Scientific) and IRDye 
signal was detected by Odyssey (LICOR).
To generate the BXPC3 tumor model, 4- to 6-wk-old female nu/nu mice (Harlan) were each 
subcutaneously inoculated in the front flank with 2 × 106 BXPC3 cells suspended in 100 μL 
of phosphate-buffered saline. Tumor size was monitored every other day, and the mice were 
used for in vivo studies when the tumors reached 4–6 mm in diameter (typically at 3–5 wk 
after inoculation of the cancer cells). The establishment of other subcutaneous tumor 
xenografts is described in the supplemental materials.
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The binding affinity of DOTA-MAb159 or DOTA-hIgG to GRP78 was evaluated through the 
bead-based binding assay following a procedure reported in the literature (11,13). The 
GRP78-binding activity of unmodified MAb159 and hIgG was also evaluated as a positive 
and negative control, respectively. Cellular uptake was analyzed as previously described 
(14). BXPC3 tumor cells were cultured in either high-glucose or glucose-free Dulbecco 
modified Eagle medium supplemented with 10% fetal bovine serum. FAM-MAb159 (10 
μg/mL) was added to the BXPC3 cells. After incubation at 37°C for 0.5 h, the cells were 
fixed with 2% paraformaldehyde and stained with 4′-6-diamidino-2-phenylindole. The cell 
uptake images were obtained with an Eclipse 80i fluorescence microscope (Nikon).
PET Imaging and Image Analysis
PET imaging and image analysis were performed using an R4 PET rodent scanner (Siemens 
Medical Solutions) or an eXplore Vista PET/ CT rodent scanner (GE Healthcare) as 
previously reported (10,15). In brief, 3.7–7.4 MBq of PET probe were intravenously injected 
into each mouse under isoflurane anesthesia. Static scans were acquired at 1, 17, and 48 h 
after injection. The images were reconstructed by 2-dimensional ordered-subsets expectation 
maximum. For each PET scan, regions of interest were drawn over the tumor and major 
organs on decay-corrected whole-body coronal images. The radioactivity concentration in 
each organ was obtained from the mean values within the multiple regions of interest and 
then converted to percentage injected dose per gram of tissue (%ID/g) (16). After all PET 
scans had been performed, the animals were sacrificed; blood, the heart, and other major 
organs were collected and weighed wet. The radioactivity in the tissue was measured using a 
γ counter (Packard Instruments). The results are presented as %ID/g. Values are expressed 
as mean ± SD for 3 animals.
Immunofluorescence Staining of Tumor Tissues
For the antibody distribution assay in tumor, 30 μg of DOTA-MAb159 or DOTA-hIgG were 
injected via the tail vein into each BXPC3 tumor– bearing mouse. At 48 h after injection, the 
mice were sacrificed and the tumors dissected. Frozen sections of tumor (8 μm) were fixed 
in 4% paraformaldehyde (Electron Microscopy Sciences) and blocked with 10% normal 
goat serum (Invitrogen). Sections were then incubated with anti-CD31 primary antibody 
overnight at 4°C, followed by the corresponding secondary antibody for 1 h at room 
temperature. Subsequently, the slides were covered with Vecta-shield mounting medium 
(Vector Labs) with 4,6-diamino-2-phenylindole and images were obtained with an Eclipse 
80i fluorescence microscope (Nikon). Secondary antibody goat anti-human Alexa Fluor 568 
and goat anti-rat Alexa Fluor 488 were used to detect antibodies (hIgG or MAb159) and 
CD31, respectively. Preparation of HT29 and PC3 tumor sections and CD31 staining of 
these sections are described in the supplemental materials.
Statistical Analysis
Quantitative data were expressed as mean ± SD. Means were compared using 1-way 
ANOVA and the Student t test. P values of less than 0.05 were considered statistically 
significant.
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In the DOTA conjugation reaction, 20 equivalents of DOTA-NHS were added to the 
MAb159 or hIgG under slightly basic conditions (Fig. 1). After a 10-h incubation at 4°C, 
PD-10 purification afforded DOTA-MAb159 and DOTA-hIgG in 82% and 75% yield, 
respectively. The average number of DOTAs in each antibody was not determined. 64Cu 
labeling for DOTA-MAb159 and DOTA-hIgG was achieved in pH 5.5 sodium acetate 
solution with decay-corrected yields of 56% and 42%, respectively. The specific activity of 
the final product was estimated to be 0.8 MBq/μg of antibody.
Western Blotting
Measured by Western blotting, GRP78 expression levels were determined in a human 
pancreatic cancer cell line (BXPC3) and a human lung cancer cell line (NCI-H249) (Fig. 2). 
The cells were cultured in either high-glucose or glucose-free Dulbecco modified Eagle 
medium supplemented with 10% fetal bovine serum. The glucose-free conditions were used 
to mimic a nutrient-deprived tumor microenvironment, which reports have shown recruits a 
greater amount of MAb159 to the surface of cancer cells under stress (17,18). Both BXPC3 
and NCI-H249 cultured in the high-glucose medium showed GRP78 expression (Fig. 2A). 
As expected, cells cultured in glucose-free medium showed more than 100% GRP78 
expression when β-actin was used as an internal standard for quantification (Fig. 2B). With 
the Western blot results in hand, we chose the BXPC3 cell line for the following in vivo 
study.
In Vitro Characterization of MAb159 Probes
To prove that labeling of DOTA did not alter the activity of MAb159, we performed a 
binding affinity experiment with unlabeled MAb159 as a reference. Setting MAb159 as 
100%, DOTA-MAb159 retained 85.35% 6 4.10% binding activity (n = 3). As a negative 
control, DOTA-hIgG showed negligible binding to GRP78 (0.055% 6 0.001%, n = 3). These 
results confirmed that DOTA has a minimum effect in reducing the binding affinity of 
MAb159 to GRP78 receptor. In addition, the cellular uptake of FAM-MAb159 was also 
tested on BXPC3 tumor cells cultured in both high-glucose and glucose-free medium (Fig. 
3). In the high-glucose group, relatively low cell uptake was observed. In contrast, the 
glucose-free group showed a much higher level of FAM-MAb159 uptake. Considering the 
differences in expression level of GRP78 between the high-glucose and glucose-free groups, 
we concluded that FAM-MAb159 uptake is specific to GRP78 receptors.
Small-Animal PET and Image Analysis
The tumor-targeting efficacy of 64Cu-DOTA-MAb159 was evaluated by static small-animal 
PET scans in BXPC3 tumor– bearing mice. Representative decay-corrected coronal PET 
images obtained at different time points are shown in Figure 4. 64Cu-DOTA-hIgG was used 
as a negative control for side-by-side comparison. At 1 h after injection, both 64Cu-DOTA-
MAb159 and 64Cu-DOTA-hIgG were circulating mainly in the blood pool. The BXPC3 
tumors were clearly visualized in the 64Cu-DOTA-MAb159 group, with good tumor-to-
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background contrast at late time points. The activity accumulation of 64Cu-DOTA-MAb159 
in BXPC3 tumors was 4.3 ± 1.2, 15.4 ± 2.6, and 18.3 ± 1.0 %ID/g at 1, 17, and 48 h after 
injection, respectively. In contrast, the activity accumulation of 64Cu-DOTA-hIgG in BXPC3 
tumors was 4.8 ± 0.5, 7.5 ± 0.7, and 4.6 ± 0.8 %ID/g at 1, 17, and 48 h after injection, 
respectively. Except for the 1-h time point, 64Cu-DOTA-MAb159 demonstrated significantly 
higher tumor uptake than 64Cu-DOTA-hIgG (P < 0.05). Other than tumor uptake, both 64Cu-
DOTA-MAb159 and 64Cu-DOTA-hIgG showed similar distribution patterns in normal 
organs such as the liver and kidney and in muscle. At the 1-h time point, tumor-to-muscle 
contrast for 64Cu-DOTA-MAb159 was 1.40 ± 0.30. With the continued accumulation 
of 64Cu-DOTA-MAb159 in BXPC3 tumors, the tumor-to-muscle ratio increased to 7.4 ± 4.6 
at 17 h after injection and to 11.5 ± 7.2 at 48 h after injection.
To further validate the PET quantification, biodistribution by direct tissue sampling was 
determined immediately after the PET scans (Fig. 5). BXPC3 tumor uptake for 64Cu-DOTA-
MAb159 and 64Cu-DOTA-hIgG was 13.1 ± 1.7 and 5.3 ± 0.6 %ID/g, respectively. In 
contrast, uptake in other normal organs did not significantly differ between 64Cu-DOTA-
MAb159 and 64Cu-DOTA-hIgG (P > 0.05). The biodistribution results were consistent with 
the PET quantification.
The tumor-targeting efficacy of 64Cu-DOTA-MAb159 was also evaluated by static small-
animal PET scans of mice bearing human colorectal cancer HT29 and human prostate 
cancer PC-3 tumors. Representative PET images are shown in Supplemental Figure 1. The 
activity accumulation of 64Cu-DOTA-MAb159 in PC3 was 2.1 ± 0.5, 3.8 ± 0.5, and 4.2 
± 0.1 %ID/g at 1, 24, and 48 h after injection, respectively, which was significantly higher 
than in muscle (0.4 ± 0.1, 0.5 ± 0.4, and 0.2 ± 0.1 %ID/g at 1, 24, and 48 h after injection, 
respectively) (Supplemental Fig. 2A). Similar results were observed for HT29 xenografts. 
The activity accumulation of 64Cu-DOTA-MAb159 in HT29 tumor was 2.6 ± 0.4, 4.4 ± 1.3, 
and 4.5 ± 1.3 %ID/g at 1, 24, and 48 h after injection, respectively, which was significantly 
higher than in muscle (0.4 ± 0.1, 0.4 ± 0.1, and 0.2 ± 0.01 %ID/g at 1, 24, and 48 h after 
injection, respectively) (Supplemental Fig. 2B).
Immunofluorescence Staining of Tumor Tissue
To further confirm that MAb159 targeted GRP78 on tumor cell surfaces in vivo, we stained 
the tumor tissue using intravenously injected MAb159 as the primary antibody and goat 
anti-human antibody conjugated with Alexa Fluor as the secondary antibody. Images were 
obtained under identical conditions and displayed at the same scale so that the relative 
brightness observed in the images reflected the difference in relative MAb159 and hIgG 
concentrations (Fig. 6). For MAb159, a strong red signal was observed in tumor tissue, 
indicating prominent accumulation of the antibody. The negative control hIgG distributed 
only minimally in BXPC3 tumors. Similar results were observed for the HT29 and PC3 
tumor models (Supplemental Fig. 3). Both the biodistribution studies and the 
immunofluorescence staining studies confirmed that MAb159 was specifically targeting the 
GRP78 receptor.
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Accumulative works have demonstrated that GRP78 protein, a master switch in endoplasmic 
reticulum stress, plays a pivotal role in cancer cell proliferation, angiogenesis, and 
chemoresistance (6,19,20). GRP78 localizes mainly in the endoplasmic reticulum, but 
GRP78 can also relocate to the cell membrane. Cell-surface GRP78 expression has been 
detected in many different cancers, such as breast, liver, prostate, and pancreatic, and has 
been associated with the development of drug resistance and cell transformation (17,21–23). 
These findings, coupled with the observation that peptides targeting GRP78 homed 
predominantly into tumor tissues but much less into normal organs suggest that cell-surface 
GRP78 might serve as a novel target for cancer-specific imaging and drug delivery. MAb159 
specifically recognizes cell-surface GRP78 and thus can be used to image the tumor for 
personalized medicine and to determine whether the amount of surface GRP78 in the tumor 
indicates disease progression or response to therapy. In this study, we developed a MAb159-
based noninvasive PET imaging probe to visualize and quantify GRP78 expression in tumor-
bearing mice in vivo.
In our approach, the novel 64Cu-labeled MAb159 antibody was synthesized and 
characterized to demonstrate that imaging GRP78 expression with PET is feasible. 64Cu was 
attached to MAb159 using a commercially available bifunctional chelator, DOTA. The 
binding activity assay showed that DOTA-MAb159 preserved 85.35% ± 4.10% of GRP78-
binding activity, compared with unmodified MAb159. We used glucose-free conditions to 
mimic nutrient deprivation in the tumor microenvironment, and we performed Western 
blotting to analyze GFR78 expression levels in tumor cells. The Western blot results 
demonstrated significantly higher GRP78 expression in tumor cells cultured in glucose-free 
medium than in tumor cells cultured in high-glucose medium (Fig. 2). The cell uptake study 
further confirmed that MAb159 could bind to glucose-starved BXPC3 tumor cells, which 
had a higher GRP78 expression level, but not to BXPC3 tumor cells cultured in high-glucose 
medium, which had lower GRP78 expression (Fig. 3).
The in vivo small-animal PET imaging study was performed on mice bearing BXPC3 tumor 
xenografts (Figs. 4 and 7). 64Cu-DOTA-MAb159 and 64Cu-DOTA-hIgG showed similar 
distribution patterns in normal organs such as the liver and kidney and in muscle. 
However, 64Cu-DOTA-MAb159 uptake in BXPC3 tumors increased over time, with 
maximum tumor uptake being 18.3 ± 1.0 %ID/g at 48 h after injection. Both active uptake 
(by MAb159-GRP78 interaction) and passive uptake (by the enhanced permeability and 
retention effect) led to 64Cu-DOTA-MAb159 accumulation in BXPC3 tumors. In contrast, 
accumulation of 64Cu-DOTA-hIgG in tumors was caused only by passive uptake, with a 
peak of 7.5 ± 0.7 %ID/g at 24 h after injection. Ex vivo biodistribution studies further 
validated the PET imaging results. BXPC3 tumor uptake of 64Cu-DOTA-MAb159 and 64Cu-
DOTA-hIgG was 14.9 ± 0.7 and 3.3 ± 0.6 %ID/g, respectively. Although nontargeting 64Cu-
DOTA-hIgG also accumulated somewhat in BXPC3 tumors, the significant difference in 
uptake between 64Cu-DOTA-MAb159 and 64Cu-DOTA-hIgG would result from the GRP78 
targeting. In addition, 64Cu-DOTA-MAb159 showed significantly higher uptake in both 
HT29 and PC3 xenografts (Supplemental Fig. 1) than in nontargeted tissue such as muscle, 
further indicating specific GRP78 targeting of 64Cu-DOTA-MAb159. In this study, we used 
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a subcutaneous tumor model. Although not orthotopic and not representing appropriate sites 
for human tumors, these models are easy to establish and have predictable and reproducible 
tumor growth. In addition, by combining ultrasound and photoacoustic imaging, several 
independent groups have found and measured hypoxia and poor blood perfusion in 
subcutaneous tumors (24–26). Therefore, subcutaneous xenograft models should be useful 
in preliminary evaluations of PET imaging of stress-induced GRP78 upregulation 
using 64Cu-DOTA-MAb159. Although we observed prominent and specific tumor uptake 
with 64Cu-DOTA-MAb159, DOTA chelating agents may potentially lose 64Cu from the 
conjugate in vivo, leading to high uptake in the liver. Other stable chelators, including 
sarcophagine cage, NOTA, or cross-bridged chelators, will be considered in our follow-up 
study if the agent is used mainly as a diagnostic probe. Nonetheless, DOTA is able to chelate 
other therapeutic radiometals (such as 177Lu and 90Y), which may allow us translate the 
DOTA-based imaging agent to a radiotherapeutic agent by changing the radiometal to a 
therapeutic isotope. We used the universal chelator DOTA, which can complex a wide 
variety of both imaging and therapeutic radioisotopes. The same DOTA-MAb159 conjugate 
can therefore readily be used for both imaging and therapeutic applications without 
significant alteration of its pharmacokinetic and tumor-targeting efficacy.
It has been reported that endoplasmic reticulum stress is activated and expression of GRP78 
is upregulated in both acute (27) and chronic (28) rodent pancreatitis models. Therefore, the 
use of MAb159-based molecular imaging probes may not be advantageous in the differential 
diagnosis of pancreatic cancer from pancreatitis. However, this issue may be less significant 
in the clinical application of MAb159-based GRP78 imaging because GRP78 upregulation 
is associated more with cancer progression and development of chemoresistance than with 
early differential diagnosis of pancreatic cancer (29). After initially responding, tumors 
eventually become resistant to chemotherapy, accounting for the death of most cancer 
patients. As a main regulator of cell stress, GRP78 can serve as a biomarker in progressive 
and chemoresistant tumors. In this study, we evaluated the feasibility of using only the 
MAb159-based PET probe for GRP78 imaging. One potential application of MAb159-based 
GRP78 imaging probes will be monitoring tumor aggressiveness and chemoresistance 
during treatment. Our preliminary data showed that after treatment with 50 μM gemcitabine 
for 24 h, HT29 cells demonstrated increased Cy5.5-MAb159 binding (Supplemental Fig. 4) 
and significantly increased cell uptake of 64Cu-DOTA-MAb159 (Supplemental Fig. 5). In 
contrast, HT29 cell binding and uptake of Cy5.5-IgG and 64Cu-DOTA-IgG were unchanged 
or slightly decreased by gemcitabine treatment. Because the cells were not permeabilized in 
the experiments, the increased binding of Cy5.5-MAb159 indicates that the cell-surface 
GRP78 level increased after treatment. Although the in vitro data showed promising results, 
GRP78 expression level is a master switch in endoplasmic reticulum stress and thus will be 
regulated by many factors, including blood flow, tumor size, and hypoxia. To confirm the 
correlation between cell-surface GRP78 and treatment results in vivo, our follow-up study 
will have a more comprehensive experimental design, including a larger sample size, a 
variety of tumor models, more treatment regimes, the optimal imaging windows, and the 
correlation between imaging changes and cell-surface GRP78 expression.
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We have developed a receptor-targeted PET probe for detection of GRP78 upregulation in 
pancreatic tumor xenografts and other tumor models. This study showed that 64Cu-DOTA-
MAb159, based on a humanized GRP78-specific monoclonal antibody, displays high target 
specificity both in vitro and in vivo. The potential correlation between cell-surface GRP78 
expression levels and tumor chemoresistance in multiple types of cancer makes 64Cu-
DOTA-MAb159 a clinically translatable agent for monitoring progression of tumors and 
development of chemoresistance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Conjugation reaction for DOTA-NHS and DOTA-MAb159.
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(A) GRP78 protein levels were determined by Western blotting in BXPC3 and NCI-H249 
cell lines. Cells were cultured in either high-glucose (HG) or glucose-free (GF) Dulbecco 
modified Eagle medium supplemented with 10% fetal bovine serum. (B) GRP78/β-actin 
ratio quantification of A.
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Cellular uptake analysis of h159-FAM on BXPC3 tumor cells cultured in either high-glucose 
or glucose-free Dulbecco modified Eagle medium supplemented with 10% fetal bovine 
serum. Scale bar = 100 μm.
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Decay-corrected whole-body coronal small-animal PET static scans of mice bearing BXPC3 
tumors. Images were obtained at 1, 17, and 48 h after injection of 64Cu-DOTA-MAb159 
or 64Cu-DOTA-hIgG. Arrowheads indicate tumors.
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Direct tissue sampling for radioactivity quantification in major organs of mice bearing 
BXPC3 tumors at 48 h after injection of 64Cu-DOTA-MAb159 or 64Cu-DOTA-hIgG. Sm Int 
= small intestine.
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Antibody distribution analysis on BXPC3 tumor sections 48 h after injection of hIgG or 
MAb159. Scale bar = 100 μm. DAPI 5 4′-6-diamidino-2-phenylindole.
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PET quantification of radioactivity in major organs of mice bearing BXPC3 tumors after 
injection of 64Cu-DOTA-MAb159 or 64Cu-DOTA-hIgG.
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